buy solid cabometyx remov
messag report fundament strong financi result slightli
street consensu think remov overhang competit concern
cabometyx growth kidney cancer rcc acceler follow approv new
combin front-lin rcc consist thesi liver cancer
remain track new discoveri collabor aurigen augment earli
stage pipelin remain fundament attract valu view trade
next year earn grow top-lin adjust estim maintain
cabometyx sale slightli street consensu strong sequenti volum
growth report total revenu street
consensu product sale slightli beat street consensu
sequenti qoq cabometyx growth almost entir driven volum
chang channel inventori call manag highlight continu
favor market dynam despit recent approv launch io/io checkpoint
inhibitor tki combin cabometyx market share continu stabl rcc
grow rcc prefer treatment patient progress line
therapi launch continu track intern expect note on-
label uptak academ commun center drive overal
phase label expans trial cabometyx remain on-track among
investor may focu readout recal
-sponsor trial random nivolumab cabometyx sunitinib
rcc trial recent complet enrol remain track interim
readout addit management highlight enrol progress
evalu addit cabometyx-bas regimen radioiodin refractori dtc
rcc respect
increas focu early-stag partner aurigen advanc
oncolog anti-inflammatori program term agreement
make up-front payment exclus option in-licens aurigen discoveri
program initi addit discoveri program option in-
licens addit per program compani highlight aurigen small
molecul discoveri expertis track record advanc asset clinic trial
also earli stage deal place icon therapeut inverva stemsynergi
within earli stage portfolio preclin program current underway
updat estim account result new opex guidanc maintain
buy rate pt end bn cash invest
modestli updat cabometyx revenu estim account result
also increas oper expens forecast given updat fy guidanc
 spend previous due busi develop
expens maintain buy pt
page analyst certif import disclosur
valuat risk
valu inc per share use dcf base valuat method
valuat includ commerci product cabometyx cometriq well probability-adjust cash
flow deriv compani pipelin royalti out-licens program use
discount rate termin growth rate appli termin year post-assum
gener entri cabozantinib
risk valuat inc includ regulatori commerci setback potenti
emerg new competitor lower product sale expect
page analyst certif import disclosur
licens contract revenu
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
